Conavi files amended final prospectus

Executive Summary

• Conavi Medical Corp. has filed an amended and restated final short form prospectus for a public offering of common shares and/or prefinanced common share purchase warrants.
• The offering is on a "commercially reasonable effort" agency basis, targeting gross proceeds between $12 million and $15 million.
• Net proceeds are designated for obtaining U.S. FDA 510(k) clearance for the next-generation Novasight hybrid system, executing a targeted U.S. market release, and general working capital.

Key Details

• Offering Structure: Issuance of a minimum of 26,666,667 securities and a maximum of 33,333,333 securities.
• Pricing:
  • Common Shares: 45 cents per share.
  • Prefinanced Warrants: 44.999 cents per warrant (issued in lieu of common shares at purchaser's election).
• Warrant Terms:
  • Exercise Price: 0.001 cent per common share.
  • Expiration: Perpetual (will not expire).
  • Exercise Basis: Net or cashless.
• Gross Proceeds: Between $12 million and $15 million.
• Use of Proceeds:
  • Obtain U.S. FDA 510(k) clearance for the next-generation Novasight hybrid system.
  • Complete a targeted market release in the United States.
  • Working capital and other general corporate purposes.
• Agent: Bloom Burton Securities Inc.
• Agent Compensation:
  • Cash Fee: 6.5% of gross proceeds (reduced to 3.25% for "president's list" purchasers).
  • Compensation Options: 6.5% of the aggregate number of securities issued (no options for "president's list" purchasers).
  • Option Terms: Entitles holder to buy one common share at the offering price; exercisable for 24 months following the closing date.
• Timeline:
  • Prospectus Filed: January 7, 2026 (Amended and Restated Final Short Form Prospectus).
  • Previous Prospectus: December 18, 2025.
  • Expected Initial Closing: On or about January 13, 2026.
• Regulatory Status: Sale of securities is contingent upon the receipt of a receipt for the A&R final prospectus and necessary regulatory/stock exchange approvals (including TSX Venture Exchange).
• Jurisdictions: Offered in Canada (Alberta, British Columbia, Ontario) and anticipated private placement in certain jurisdictions outside Canada.

Notable Quotes

• None provided in the text.